Skip to main content

Table 2 Ongoing treatments

From: COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

 COVID-19 patients, N pts/N evaluable (%)RNA-positive subgroup, N pts/N evaluable (%)
Early breast cancer patientsN = 22N = 22
 Surgery*3/22 (14%)3/22 (14%)
 Chemotherapy8/22 (36%)8/22 (36%)
  Epirubicin and cyclophosphamide5/22 (23%)5/22 (23%)
  Paclitaxel/docetaxel2/22 (9%)2/22 (9%)
 Radiation therapy2/22 (9%)2/22 (9%)
 Endocrine therapy4/22 (18%)4/22 (18%)
  Anti-estrogens3/22 (14%)3/22 (14%)
  Aromatase inhibitors1/22 (4%)1/22 (4%)
 Targeted therapy3/22 (14%)3/22 (14%)
  Trastuzumab2/22 (9%)2/22 (9%)
  Pertuzumab1/22 (4%)1/22 (4%)
  Trastuzumab emtansine1/22 (4%)1/22 (4%)
 None6/22 (27%)6/22 (27%)
  Pending surgery5/22 (23%)5/22 (23%)
  Pending radiation therapy1/22 (4%)1/22 (4%)
 Combination of any treatment3/22 (14%)3/22 (14%)
Metastastic breast cancer patientsN = 37N = 19
 Surgery*0 (0%)0 (0%)
 Chemotherapy21/37 (57%)10/19 (53%)
  Capecitabine7/37 (19%)4/19 (21%)
  Paclitaxel/docetaxel6/37 (16%)3/19 (16%)
  Epirubicin and cyclophosphamide1/37 (3%)0 (0%)
  Vinorelbine2/37 (5%)0 (0%)
  Eribulin1/37 (3%)1/19 (5%)
  Gemcitabine2/37 (5%)1/19 (5%)
  Carboplatin3/37 (8%)1/19 (5%)
  Intrathecal chemotherapy2/37 (5%)2/19 (10%)
 Radiation therapy2/37 (5%)2/19 (10%)
 Endocrine therapy15/37 (40%)7/19 (37%)
  Anti-estrogens3/37 (8%)1/19 (5%)
  Aromatase inhibitors11/37 (30%)6/19 (32%)
  Selective estrogen receptor degrader1/37 (3%)0 (0%)
 Targeted therapy16/37 (43%)7/19 (37%)
  CDK4/6 inhibitor9/37 (24%)5/19 (26%)
  Trastuzumab5/37 (13%)2/19 (10%)
  Pertuzumab4/37 (11%)2/19 (10%)
  Everolimus**2/37 (5%)0 (0%)
 Immunotherapy0 (0%)0 (0%)
 Combination of any treatment21/37 (57%)8/19 (42%)
 None1/37 (3%)1/19 (5%)
TotalN = 59N = 41
  1. Listed treatments were those ongoing within 30 days before COVID-19 diagnosis
  2. *Ongoing surgery includes 30 days from surgery
  3. **As recommended, patients stopped everolimus at the beginning of the pandemic